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Background
Copy number variants (CNVs) are established risk factors for
neurodevelopmental disorders. To date the study of CNVs in
psychiatric illness has focused on single disorder populations.
The role of CNVs in individuals with intellectual disabilities and
psychiatric comorbidities are less well characterised.
Aims
To determine the type and frequency of CNVs in adults with
intellectual disabilities and comorbid psychiatric disorders.
Method
A chromosomal microarray analysis of 599 adults recruited from
intellectual disabilities psychiatry services at three European
sites.
Results
The yield of pathogenic CNVs was high – 13%. Focusing on
established neurodevelopmental disorder risk loci we find a
significantly higher frequency in individuals with intellectual
disabilities and comorbid psychiatric disorder (10%) compared
with healthy controls (1.2%, P<0.0001), schizophrenia (3.1%,
P<0.0001) and intellectual disability/autism spectrum disorder
(6.5%, P < 0.00084) populations.
Conclusions
In the largest sample of adults with intellectual disabilities and
comorbid psychiatric disorders to date, we find a high rate of
pathogenic CNVs. This has clinical implications for the use of
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Neurodevelopmental disorders are a group of disorders that are
characterised by perturbed neurodevelopment –intellectual disabil-
ities, autism spectrum disorder (ASD) and schizophrenia are all
considered to be neurodevelopmental disorders.1 A proportion of
the risk for neurodevelopmental disorders can be attributed to a
class of genetic variants known as copy number variants (CNVs).2
A CNV is typically defined as a segment of DNA >1 kilobase,
which is present at a higher (duplication) or lower (deletion)
copy number compared with a reference genome.3 Intellectual dis-
ability has its onset in childhood and initially manifests with failure
to meet developmental milestones, known as developmental delay.
In adulthood, a clinical diagnosis of intellectual disability is typically
given when there are both deficits in adaptive and intellectual
functioning (IQ score <70). Intellectual disability can occur in iso-
lation or in combination with a range of somatic, psychiatric and
behavioural disorders. Association studies have shown the in-
volvement of CNVs in psychiatric risk, in particular CNVs have
been strongly implicated in the aetiology of schizophrenia4 and
ASD.5 Furthermore, investigations in large paediatric cohorts
have revealed CNV regions that are significantly associated with
intellectual disabilities.6 Many of these CNVs operate across trad-
itional diagnostic boundaries: for example, 11 of the CNVs
associated with intellectual disabilities are also risk factors for
schizophrenia.7 The neurodevelopmental disorder risk CNVs that
have been identified to date confer moderate to large risk (odds
ratio 1.5 to ≥50),7 and therefore have important clinical implica-
tions for affected individuals and at-risk family members.
A major challenge in the clinical interpretation of CNVs is the
variable penetrance and expressivity of many neurodevelopmental
disorder risk CNVs. For example, not all individuals with a particu-
lar CNV display a neurodevelopmental phenotype (penetrance) and
not all individuals express a severe phenotype (expressivity).8 A
large proportion, approximately 50%, of adult intellectual disability
is idiopathic or of unknown cause.9 Chromosomal microarray ana-
lysis (CMA), the group of tests used to detect CNVs, have been one
of the recommended first-tier tests for clinical investigation of idio-
pathic intellectual disabilities since around 2010 and have primarily
been undertaken in paediatric populations.10 Testing of adults with
intellectual disabilities is particularly important for elucidating the
relationship between rare CNVs and late-onset medical and psychi-
atric phenotypes. Indeed, the highest burden of pathogenic CNVs
may be present in adults expressing comorbid neurodevelopmental
phenotypes.
Method
To the best of our knowledge, this study is the first multipopulation
analysis of CNVs in adults with intellectual disabilities and psychi-
atric comorbidities and represents the largest sample of its kind to
date. We aimed to determine: (a) the frequency of known neurode-
velopmental disorder risk CNVs compared with large population
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cohorts from the literature (healthy controls, individuals with intel-
lectual disabilities/ASD and schizophrenia);7 (b) the overall rate of
pathogenic CNVs; (c) the relationship between pathogenic CNVs,
level of intellectual disability and comorbid psychiatric diagnoses;
and (d) likely pathogenic CNVs affecting neurodevelopmental can-
didate genes.
Participant recruitment
The GENMID (GENetics of Mental disorders in Intellectual
Disability) consortium is comprised of three primary research
groups based in Catalonia, Spain; Leuven, Belgium; and England,
UK. In Catalonia participants were identified between 2009 and
2012 from the mental health intellectual disabilities regional com-
munity service at Parc Hospitalari Martí i Julià, Girona. In
Leuven, participants were recruited between 2005 and 2015 at the
regional in-patient psychiatric unit for adults with intellectual dis-
abilities at the St Camillus Psychiatric Hospital, Bierbeek. Initially,
only patients diagnosed with psychosis were recruited, but recruit-
ment was later extended to other psychiatric phenotypes. In
England, participants were recruited by consultant psychiatrists in
intellectual disabilities between 2012 and 2015 from intellectual dis-
ability psychiatry case-loads at 32 National Health Service (NHS)
trusts and 1 non-NHS provider.
Written informed consent was obtained for all participants with
capacity to consent and consultee/guardian advice was sought in the
absence of this. Approval in England was granted by the North
Wales Research Ethics Committee West, reference 11/WA/0370.
In Catalonia approval was granted by Catalonia Corporació
Sanitària Parc Taulí Ethics Coomittee reference 2009/582. In
Leuven approval was granted by the Commissie Medische Ethiek
van de Universitaire Ziekenhuizen KU Leuven, reference S54583
(ML8614).
Recruitment criteria
All sites recruited adults over the age of 18 years. Participants had
idiopathic intellectual disabilities, defined as no clear genetic or
environmental cause of intellectual disabilities as detailed in their
medical records. Participants had one or more comorbid psychiatric
diagnoses and/or significant challenging behaviours.
Phenotypic assessments
For all sites the intellectual disability levels are in accordance with
the ICD-10 ranges (<20 profound intellectual disabilities, 20–34
severe intellectual disabilities, 35–49 moderate intellectual disabil-
ities, 50–69 mild intellectual disabilities, 70–84 borderline intellec-
tual disabilities).11 For further analyses, the <20–49 ranges were
collapsed into a severe category and the 50–84 ranges were collapsed
into a mild category. All sites identified psychiatric diagnoses from
medical records and/or informants. Psychiatric diagnoses were con-
verted from DSM-IV12 to ICD-10 criteria (with agreement between
two psychiatrists).
Genetic analysis and CNV calling
DNA was extracted from blood and saliva samples. Samples from
Catalonia were analysed using the 400 K Agilent platform
(Agilent Technologies, Santa Clara, California, USA) at the Genetics
Laboratory, UDIAT-Centre Diagnòstic, Parc Taulí Hospital
Universitari. Samples from Leuven were analysed on the CytoSure
ISCA oligoarray set (OGT, Oxford, UK) at the Constitutional
Cytogenetics Unit of the Center of Human Genetics. Samples from
England were analysed on the NimbleGen 135 K platform (87%)
(Roche NimbleGen, Madison, Wisconsin, USA) and the Cytoscan
750 K platform (13%) (Affymetrics, Santa Clara, California, USA)
at the North East Thames Regional Genetics Service Laboratory.
CNV calling took place at the respective clinical laboratories, in
keeping with internal laboratory protocols based on the American
College of Medical Genetics best guidelines13 or the Association of
Clinical Genetic Science Best Practice Guidelines.14
CNVs reported by the clinical laboratories were classified into
three categories: pathogenic, uncertain clinical significance and
benign. The genome coordinates for all sites are reported according
to the National Center for Biotechnology Information (NCBI)
human genome build 37 (hg19, February 2009). All pathogenic
CNVs were fed back to the participants’ treating psychiatrist.
Analysis methodology
We aimed to compare the rate of known rare neurodevelopmental
disorder risk CNVs in our cohort with rates in other patient
populations. We used a list of 63 neurodevelopmental disorder
risk CNVs from Rees et al,7 originally derived from Coe et al.6
The patient population rates in healthy controls, ID/ASD (the
name given by Rees et al to a severe developmental disorders
cohort), and schizophrenia were derived from Rees et al,7 where
further information can be found about the respective samples.
Neurodevelopmental disorder CNV carriers were identified using
the criteria outlined in Kendall et al,15 also used by Rees et al7
(George Kirov, personal communication via email, 27/10/2016)
(see Supplementary Table 1 available at https://doi.org/10.1192/bjp.
2017.65). CNVs fulfilling these calling criteria were classified as
pathogenic and are included in the diagnostic yield. Duplications
(dup) or deletions (del) of the same chromosomal region were
counted as separate loci (for example 22q11.2 del and dup). A rate
percentage was calculated to enable comparisons between different
sample sizes and chi-squared tests were used to determine the popu-
lation differences. The significance level has been adjusted to P = 0.01
to account for multiple pairwise comparisons.
To determine the CMAyield each individual was grouped by the
most pathogenic CNV detected. Between site discrepancies were
reclassified in accordance with Kearney et al13 (see Supplementary
Table 2). CNVs designated as of uncertain clinical significance
were reclassified into likely benign or likely pathogenic using this
methodology. We examined all likely pathogenic CNVs for recur-
rence and describe the main loci that have been implicated as neu-
rodevelopmental disorder risk factors in the current literature.
Finally, we performed chi-squared tests (or Fisher’s exact where
there were five or less individuals) to examine the differences
between psychiatric diagnoses, intellectual disability level and
CNV pathogenicity. Since many of the comorbid diagnoses are corre-
lated and thus are non-independent, correction of P-values through
Bonferroni or other methods was deemed too stringent. Thus, we
present all P-values uncorrected for multiple testing as recommended
by several authors,16,17 while indicating the number of tests performed
if all comparisons are not presented. All analyses were performed
using R version 3.3.1.18
Results
We recruited 599 adults (Catalonia, n = 80; Leuven, n = 272; and
England, n = 247) with intellectual disabilities and one or more
comorbid psychiatric diagnoses/challenging behaviours (376
(62.8%) male, mean age 43.2). Just more than half of the sample
(50.8%) had severe intellectual disabilities and the remainder had
mild intellectual disabilities. Each participant had on average 1.6
comorbid psychiatric diagnoses, with pervasive developmental disor-
ders being themost frequent diagnosis (25%), followed by unspecified
non-organic psychosis (20%) (Table 1 and Supplementary Table 3).
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The average number of CNVs per participant was 12.5 (7.4 deletions
and 5.5 duplications). Analysis of mean CNV size revealed that
pathogenic CNVs were the largest followed by likely pathogenic,
and both categories were significantly larger than likely benign and
benign CNVs (Supplementary Fig. 1). In line with guidelines of
CNV categorisation our results follow the expected size distribution
in that pathogenic CNVs are the largest.
Neurodevelopmental CNV frequency analysis
In our sample, we found CNVs in 23 of the 63 neurodevelopmental
disorder loci described by Rees et al.7 At these 23 loci we identified
58 CNV carriers, with 2 individuals carrying two risk CNVs. The
rate percentage in our sample (rate of participants with a neurode-
velopmental disorder CNV) is 10.0%, whereas the rate percentage,
determined from the data presented in Rees et al, is 6.5% in the
intellectual disability/ASD, 3.1% in the schizophrenia and 1.2% in
the healthy control populations (Table 2).7 The neurodevelopmen-
tal disorder loci frequencies are most comparable with the intellec-
tual disability/ASD population, a sample that consisted mainly of
children with developmental delay/intellectual disabilities and/or
ASD.6,7 However, we still observe significantly higher proportions
of neurodevelopmental disorder CNVs in our intellectual disabil-
ities and comorbid psychiatric diagnosis sample, 3.5% higher
(95% CI 1–6, P = 0.00084).
The frequencies of the 23 neurodevelopmental disorder CNVs
identified in this cohort are shown in Fig. 1. The carrier frequency
at each loci was the highest in our sample of people with intellectual
disabilities and comorbid mental illness, with the exception of four
loci for which we see comparable frequencies with the intellectual
disability/ASD cohort. The five most frequent neurodevelopmental
disorder CNVs in the GENMID cohort, in order of frequency, are:
22q11.2 del (n = 7, 1.2%), 15q11.2 Prader–Willi syndrome/
Angelman syndrome (PWS/AS) dup (n = 6, 1%), 16p11.2 dup
(n = 5, 0.8%), 15q13.3 del (n = 5, 0.8%) and 16p12.1 del (n = 4,
0.7%). A description of all CNV loci and the carrier phenotypes
can be found in Supplementary Table 4.
Pathogenic CNV yield
In the GENMID sample 78 participants (13.0%, 95% CI 10.5–16.0)
had at least one pathogenic CNV, with similar yields found at all
research sites (Catalonia: 13.8%, Leuven: 14.0%, and England:
11.7%). Pathogenic CNVs comprised those identified at the neuro-
developmental disorder loci previously described and a further 25
CNVs reported as pathogenic by the clinical laboratory services
(see Supplementary Table 5). The pathogenic CNVs were predom-
inantly deletions (59.5%). We previously reported a rate of 11%
pathogenic CNVs in a subset of 202 of the 247 participants from
the England sample.19 When these 202 individuals are removed
from the combined sample the diagnostic yield is 13.9%, thus repli-
cating the initial finding.
Intellectual disability level, psychiatric diagnoses and
CNV pathogenicity
We examined group differences between CNV pathogenicity, psy-
chiatric diagnoses and level of intellectual disability. We observe
some differences in the proportions of intellectual disabilities and
psychiatric diagnoses between the CNV pathogenicity groups
(pathogenic, likely pathogenic, likely benign and benign;
Supplementary Fig. 2). However, no simple unidirectional relation-
ships were observed. Equally, minor differences in the severity of
intellectual disabilities were found between CNV pathogenicity
groups, but no overall unidirectional relationship was observed.
Likely pathogenic CNVs
The yield of likely pathogenic CNVs in the sample was 21.5% (95%
CI 18.4–25.1). Investigation of recurrent likely pathogenic CNVs
revealed 34 CNVs in 16 regions (Supplementary Table 6). Four recur-
rent CNVs identified here corroborate existing evidence for the
involvement of these regions in neurodevelopmental risk (Fig. 2).
First, we identified two carriers of exonic duplications in the
CNTN6 gene at 3p26.3. The CNTN proteins belong to an immuno-
globulin super family of cell adhesion molecules and have an
important role in neurodevelopmental processes.20CNTN6 duplica-
tions were first identified in patients with ASD21,22 and later in a
patient with intellectual disabilities and facial dysmorphisms.23 A
review of 14 patients with CNTN6 CNVs revealed that both CNV
deletions and duplications affecting CNTN6 are thought to be
Table 2 Rate (%) of copy number variant frequenciesa at 63 neurodevelopmental disorder risk loci in the GENetics of Mental disorders in Intellectual
Disability (GENMID) cohort compared with populations rates reported by Rees et al (2016)7
Sample Sample size
Rate of the 63 neurodevelopmental
disorder loci, %
Rate difference,
% (95% CI), P
Healthy control 26 628 1.2 8.8 (6.3–11) 2.8 × 10–72
Schizophrenia 20 403 3.1 7 (4.5–9.5) 9.7 × 10–21
Intellectual disability/autism spectrum disorder 29 085 6.5 3.5 (1–6) 8.4 × 10–4
GENMID 599 10.0 – –
a. Rate percentage differences, 95% CI and P-values for rate comparisons are indicated.
Table 1 Descriptive summary of GENetics of Mental disorders in




Ratio (male/female) 1.7 (376/223)
Age, mean (s.d.) 43.2 (14.1)




Number of comorbid diagnoses, mean (range) 1.6 (1–5)
F84 Pervasive developmental disorders, n (%) 148 (25)
F29 Unspecified non-organic psychosis, n (%) 121 (20)
F61 Mixed and other personality disorders, n (%) 108 (18)
Challenging behaviours, n (%) 95 (16)
F32 Depressive episode, n (%) 86 (14)
F41 Other anxiety disorders, n (%) 60 (10)
F20 Schizophrenia, n (%) 49 (8)
F31 Bipolar affective disorder, n (%) 47 (8)
F90 Hyperkinetic disorders, n (%) 41 (7)
F42 Obsessive–compulsive disorder, n (%) 37 (6)
F43 Reaction to severe stress and adjustment disorders,
n (%)
27 (5)
F39 Unspecified mood disorder, n (%) 25 (4)
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involved in variable neuropsychiatric phenotypes.24 The partici-
pants identified in our study both presented with mild intellectual
disabilities. One had schizophrenia and personality disorder, and
one had challenging behaviours and had been convicted of a
serious criminal offence. Interestingly, the participant with schizo-
phrenia and personality disorder also had a duplication in the
CNTN4 gene. CNVs affecting CNTN4 are also thought to confer
risk for various neurodevelopmental disorders.25
Second, we identified two participants with CNV duplications
at the 9q21.32q21.33 locus encompassing the SLC28A3 and
NTRK2 genes. SLC28A3 is a nucleoside transporter involved in
the regulation of multiple processes, including neurotransmis-
sion; however, there are no prior reports of its role in psychiatric
risk. NTRK2 is a receptor tyrosine kinase with numerous neuro-
developmental functions, including synapse formation and plas-
ticity. Altered NTRK2 expression has been identified in the
brains of patients with schizophrenia.26 One participant had
severe intellectual disabilities and bipolar disorder, and the
other had mild intellectual disabilities with unspecified non-
organic psychosis.
Third, we identified five participants with exonic CNVs in the
CHD gene family. The CHD proteins are involved in chromatin
structure remodelling and the epigenetic regulation of transcription.
Three of the participants had exonic CNVs (2 duplications, 1 dele-
tion) in the CHD8 gene at 14q11.2, which also encompass
SUPT16H. The protein encoded by the SUPT16H gene is thought
to be involved in DNA replication and repair. CNV deletions affect-
ing CHD8 and SUPT16H were initially described in children with
developmental delay and dysmorphic features.27 Variants in the
CHD8 gene are thought to confer a phenotypic subtype of ASD,
comprising macrocephaly, facial dysmorphologies and gastrointes-
tinal abnormalities.28 Both deletions29 and duplications30,31 affect-
ing CHD8 and SUPT16H have been described with variable
neurodevelopmental phenotypes. The two participants with CNV
duplications both had severe intellectual disabilities, one was diag-



























































































































Fig. 1 Neurodevelopmental disorder copy number variant frequencies in the GENetics of Mental disorders in Intellectual Disability (GENMID)
sample compared with frequencies in healthy controls (n = 26 628), intellectual disability/autism spectrum disorder (ID/ASD) (n = 29 085) and
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Fig. 2 The locations of four overlapping likely pathogenic copy number variants in the GENetics of Mental disorders in Intellectual Disability cohort that are implicated in neurodevelopmental disorders in the








The participant with the CNV deletion also had severe intellectual
disabilities and ASD.
Finally, we identified two participants with exonic CNVs in the
CHD2 gene at 15q26.1 (one deletion and one duplication). Several
patients have been described with CHD2 deletions; with a
common phenotype of intellectual disabilities, epilepsy and aggres-
sive challenging behaviours.32,33 To our knowledge, a CNV duplica-
tion in CHD2 has not previously been described in the literature.
The deletion carrier had severe intellectual disabilities and schizo-
affective disorder, and the duplication carrier had challenging beha-




There is a paucity of research on CNVs in adults with intellectual
disabilities and comorbid psychiatric phenotypes. This poses a
challenge for genetic counselling of novel and rare CNVs, as
descriptions of later-life phenotypes are largely unavailable.
Previous investigations in this patient group identified a diagnostic
yield of 11% CNVs classed as clinically relevant.19 In this study,
utilising data from three European research sites, we replicate
this finding with a higher diagnostic yield of 13.0% pathogenic
CNVs in 599 participants (or 13.9% with the previously reported
cases removed). Given that CMA is being advocated for use in
cohorts with schizophrenia, in which the diagnostic yields are
lower (between 2.5 and 5%),34,35 adults with intellectual disabilities
presenting to psychiatric services appear to be a group to prioritise
for CMA.
We found CNV carriers at 23 out of the 63 neurodevelopmental
disorder loci. It is unsurprising that we did not find carriers in the
remaining 40 loci, as these CNVs are very rare with reported fre-
quencies in intellectual disabilities between 0.01 and 0.26% (mean
0.06%).7 Presuming that there is an additive effect of having both
intellectual disabilities and a comorbid psychiatric disorder, then
we would expect to see an increased frequency of the 63 neurodeve-
lopmental disorder CNVs in our cohort. Indeed, the cumulative fre-
quency was significantly higher, compared with both intellectual
disability/ASD populations not selected for psychiatric comorbidity
and individuals with schizophrenia.
The phenotypic presentation of the neurodevelopmental dis-
order CNV carriers is highly variable, both in terms of the level of
intellectual disability and the psychiatric diagnoses. This indicates
a broader role for genes within these CNV loci in conferring
general, as opposed to disorder-specific, psychiatric risk. It is pos-
sible that this clinical heterogeneity partly reflects the difficulty of
diagnosing psychiatric disorders in individuals with intellectual dis-
abilities. Interestingly, at least one CNV carrier at each of the five
most frequent loci has a psychosis phenotype. Of particular interest
are the four carriers of the 16p12.1 deletion, which was significantly
associated with risk for schizophrenia by Rees et al.7 Three of the
four carriers had a psychosis phenotype, offering further support
for this locus as a risk factor for both intellectual disabilities and
psychotic disorders.
We determined the diagnostic yield of CMA in our cohort. In
addition to the CNVs identified at known neurodevelopmental dis-
order loci, we identified a further 25 CNVs that were reported as
pathogenic by the clinical genetic services. The majority of these
were large deletion CNVs (1.7–13.2 Mb), which overlapped CNVs
described in single case reports in the existing literature. This
group of CNVs are likely to be extremely rare and thus would not
be observed at high enough frequencies in existing case–control
studies. We were unable to identify any clear relationship between
intellectual disability level, comorbid psychiatric diagnoses and
CNV pathogenicity level. This may indicate that neurodevelopmen-
tal disorder CNVs generally have pleiotropic effects; however,
research with larger sample sizes would be required to further inves-
tigate this.
We investigated likely pathogenic CNVs of uncertain clinical
significance. Following a literature review of likely pathogenic
CNVs that recur in our sample, we were able to offer further
support for the involvement of particular CNV regions in neurode-
velopmental and psychiatric risk. Unlike the pathogenic CNVs, the
likely pathogenic CNVs supporting existing neurodevelopmental
candidate loci were small (<1Mb) and affected only a small
number of genes. There is a growing body of literature for the
role of the CNTN and CHD gene families in risk for intellectual dis-
ability and comorbid psychiatric disorders. Again, the phenotypes
associated with CNVs affecting these genes appear to be highly vari-
able. It is important to consider the clinical implications of these
CNVs, which were not initially reported as pathogenic by the clin-
ical genetics services.
Implications
Our findings suggest that if CMA is to be offered more widely to
adults with intellectual disabilities presenting with mental disorders
many would receive a new genetic diagnosis. Such diagnoses have
many implications. They provide, at least, a partial explanation
for the person’s physical and mental health problems, which in
turn may have an effect on illness-related beliefs of patients, their
families and healthcare professionals. For some CNVs medical
and psychiatric associations across the life course are now well
described, with implications for clinical management. For
example, the 22q11.2 deletion has recommendations for physical
health screening, include cardiac, renal and immunology investiga-
tions and psychiatric screening.36 Although clinical recommenda-
tions for some pathogenic CNVs are less clear, it is important to
note that 70% of pathogenic CNVs we identified were in neurode-
velopmental disorder risk loci, for which there are existing scientific
literature and/or clinical disorder guides available for families and
clinicians.37 Identification of pathogenic CNVs also has broader
implications for family members, including cascade testing, provi-
sion of recurrence risk information and access to support groups.
Given the rapid progress of genomic medicine there is a need for
research to address questions of clinical utility and adverse out-
comes in order to optimise the process of genetic investigation in
intellectual disability psychiatry.
Limitations
One of the limitations of this study is that there were some dif-
ferences between the populations recruited at the different sites,
for example, participants were recruited from in-patient psychiatric
services in Leuven and primarily outpatient services in Catalonia
and England. Most individuals lacked inheritance data, which is
a valuable aid in categorisation of rare variants and may have
led to an underestimate of our yield. Different platforms were uti-
lised to detect the CNVs at the different sites; however, as all the
platforms used were high resolution this is unlikely to have
major effects. Finally, a true estimate of the association between
CNV pathogenicity and neurodevelopmental disorder phenotypes
would require much larger case–control samples or epidemio-
logical-based studies.
In conclusion, this is to our knowledge the first large multipopu-
lation study of CNVs in individuals with idiopathic intellectual dis-
abilities with comorbid psychiatric disorders. We detected a 13%
rate of undiagnosed pathogenic CNVs. From a research perspective,
studying this population revealed the highest rate of CNVs at
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established neurodevelopmental disorder loci and recurrent likely
pathogenic CNVs, both offering unique opportunities for further
phenotyping of rare variants. Increased clinical testing and research
in this population should be a priority for both clinicians and
researchers in the field of psychiatric genetics.
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Reconstructed on your living room floor,
of upturned buckets, wooden planks, tin cans,
the plastic cover of a pornographic DVD:
‘This is the Temple of Solomon,’ you said.
Hair and beard grown wild as a prophet’s –
entangled and matted as your thoughts –
an Elijah or John the Baptist, misunderstood,
intoning messages from God.
No diet of locusts and wild honey here –
only Pot Noodle on a broken stove,
in this, the wilderness you once called home.
The windows and furniture all now smashed –
the only things which had been left intact
from the whispered sorrows of your life:
the faithless wife, redundant job,
the stillborn child.
We sent you off, on Section 3, in a discreet grey van,
clutching your Bible in the cold, indifferent dawn,
to fill you up with olanzapine or clozapine until
you stop
dreaming of Jerusalem.
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